The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition
about
Language performance in Alzheimer's disease and mild cognitive impairment: A comparative reviewPlasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)The MMSE orientation for time domain is a strong predictor of subsequent cognitive decline in the elderlyAlzheimer's disease--subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studiesDual-task effects of simulated lane navigation and story recall in older adults with and without memory impairment.Prognostic Significance of Mild Cognitive Impairment Subtypes for Dementia and Mortality: Data from the NEDICES Cohort.The Combination of Dysexecutive and Amnestic Deficits Strongly Predicts Conversion to Dementia in Young Mild Cognitive Impairment Patients: A Report from the Gothenburg-Oslo MCI StudyNeuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke.Detection of visuoperceptual deficits in preclinical and mild Alzheimer's disease.Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's diseaseCognitive, genetic, and brain perfusion factors associated with four year incidence of Alzheimer's disease from mild cognitive impairment.Thyroid hormones are associated with poorer cognition in mild cognitive impairment.SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease.Cut-off scores of a brief neuropsychological battery (NBACE) for Spanish individual adults older than 44 years old.Screening for new biomarkers for subcortical vascular dementia and Alzheimer's diseaseMultimodal Discrimination of Alzheimer's Disease Based on Regional Cortical Atrophy and Hypometabolism.Neuropsychological and neuropsychiatric prediction of global cognitive status among older Spanish-speaking Hispanics and English-speaking whites.Brain perfusion correlates of visuoperceptual deficits in mild cognitive impairment and mild Alzheimer's disease.Executive Dysfunction in MCI: Subtype or Early Symptom.Dysexecutive syndrome in amnesic mild cognitive impairment: a multicenter studyRelations between Concurrent Longitudinal Changes in Cognition, Depressive Symptoms, Self-Rated Health and Everyday Function in Normally Aging Octogenarians.Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementiaNurses' role in identifying mild cognitive impairment in older adults.A two-year follow-up of cognitive deficits and brain perfusion in mild cognitive impairment and mild Alzheimer's disease.Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI.Predicting conversion to dementia in a memory clinic: A standard clinical approach compared with an empirically defined clustering method (latent profile analysis) for mild cognitive impairment subtypingCorrelation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults.Platelet Membrane β-Secretase Activity in Mild Cognitive Impairment and Conversion to Dementia: a Longitudinal StudyClinical-neuroimaging characteristics of dysexecutive mild cognitive impairment.Neuropsychiatric symptoms in mild cognitive impairment: differences by subtype and progression to dementia.Ecological assessment of executive functions in mild cognitive impairment and mild Alzheimer's disease.Semantic knowledge for famous names in mild cognitive impairment.Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.The profile of executive functioning in amnestic mild cognitive impairment: disproportionate deficits in inhibitory control.Asymmetric cerebral blood flow in patients with mild cognitive impairment: possible relationship to further cognitive deterioration.Added value and limitations of amyloid-PET imaging: review and analysis of selected cases of mild cognitive impairment and dementia.Monte Carlo feature selection and rule-based models to predict Alzheimer's disease in mild cognitive impairment.An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative.Cognitive impairment 3 years after neurological Varicella-zoster virus infection: a long-term case control study.Neural correlates of saccadic inhibition in healthy elderly and patients with amnestic mild cognitive impairment.
P2860
Q22248003-E010DC34-3F78-4985-8723-3D0E561FAD31Q24193707-0BECB54A-8EB0-44AA-8F82-878059D1A631Q24633639-CCABBBCC-7C8E-4AC3-8296-2D803F45AE4FQ26798325-7AA7475A-6312-4771-AAA2-A72814F3C156Q30440401-EAE10776-06D3-4730-BB9A-3F10AABF066BQ31036429-4B615269-1173-4A2B-B5A4-7A443A550368Q33625660-29D9347E-0FEE-4A75-AF8B-A24CC503B9B7Q33689233-F86C8B7D-6BDA-4FF7-9953-E297647AAE68Q33711721-4DF1E827-7205-4E67-A702-3DA42BEE18B1Q33895840-3E68ED9C-4210-4BC9-9959-BE62FB7AA525Q33953312-C01F7EC1-6B94-4A23-83F1-F44E22AD61EEQ34168826-5ACF2398-A474-40C9-945A-B744B5BFC416Q34620335-452FA8AB-BEBD-4460-9A4A-58A2593F5A4CQ35022765-30FC4A38-F83C-485C-AA83-2F0D5A948A94Q35428298-6FDA7C49-1B96-4C23-B652-753E280FC424Q35660011-C5CA7A0B-29DC-4448-BB39-162AA45FB00CQ35735243-3AB2996B-3E8F-41F8-B0FF-CC14F8D247C6Q35837451-F28F56EC-F63A-42FE-B63E-3C09CC020280Q36014695-1405732D-C424-45DF-AE9F-DA03C8C99B52Q36040668-32C2112E-9452-47F3-9B01-151E87C22B57Q36110122-8616BAD6-E146-441A-8062-F32EC6FFFE19Q36177038-D88F7AC8-ADEF-4C68-90C7-7B6277636C4BQ36498975-C8A461A6-999A-4B8B-B8E6-2C3D9790AEA1Q36660799-12EA5164-72F3-4C21-91AB-57A8B7662B88Q36796489-1090F8C3-38D1-4FED-B3E5-7C91B6F5305AQ36933680-A9967A53-FDA6-403D-81B2-E1DA949B8281Q37051726-C2ACB60B-5CA1-40C9-B653-79A1342E42EBQ37053743-4C88A6F7-7868-4BB2-AF7B-19648AF1E353Q37187945-A130329F-D070-463F-B3B8-E196B54C8B84Q37326875-8CE7E7FD-8D93-46CB-9C64-0826D0C3C77CQ37347911-09D0E3C9-45E3-43E3-839D-A88A23E39855Q37414019-D088DDBA-05FD-4BE0-84EB-EC188596B71DQ37721132-03CDD9C2-8782-425B-8014-6123EE5EE528Q37988692-DB4B0EE0-5953-4316-B8FA-238E0725D0F4Q38801554-439D15EB-2968-4EDA-8A07-071531CDA538Q39219904-576ABF9F-E444-46A4-93DB-86563E121179Q39619266-42174C10-7C22-4CE6-A7DD-5B577185113AQ39740912-27D20610-F4D8-4D68-885E-265D69A333C2Q42253144-FD0EBD73-069C-4EEE-98C9-CB0AE8CE92CAQ43077799-E71DD18A-51E8-4F1E-BB2B-D06E7D2B9BE6
P2860
The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition
@ast
The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition
@en
type
label
The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition
@ast
The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition
@en
prefLabel
The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition
@ast
The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition
@en
P2093
P2860
P356
P1476
The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition
@en
P2093
P2860
P304
P356
10.1136/JNNP.2004.050385
P407
P577
2005-11-01T00:00:00Z